> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Heartflow Lifts Sales Outlook To $262 Million–$264 Million As U.S. Scan Volumes Grow
- URL: https://www.bullished.co/heartflow-lifts-sales-outlook-to-262-million-264-million-as-u-s-scan-volumes-grow-3c791f66/
- Published: 2026-11-12T23:36:02.000Z
- Updated: 2026-11-12T23:36:02.000Z
- Description: Third-quarter revenue rose 57%, but spending on sales staff, technology and clinical research kept the diagnostic software company loss-making.
- Author: Matteo Parrino
- Tags: Earnings, HTFL, Industry: Healthcare

Heartflow, which uses AI to help physicians diagnose coronary artery disease from heart scans, raised its [2026 sales forecast](https://www.sec.gov/Archives/edgar/data/0001464521/000146452126000171/htfl-20261112x8k.htm?ref=bullished.co) Thursday to $262 million–$264 million from $246 million–$250 million. Its accompanying earnings release showed third-quarter revenue rising 57% to $72.9 million, primarily from more U.S. blood-flow and plaque analyses.

## U.S. Analyses Drive The Upgrade

The new outlook puts expected annual revenue growth at approximately 49%–50%, against approximately 40%–42% previously. Heartflow also lifted its adjusted gross-margin forecast to approximately 82.5% from approximately 82%.

U.S. revenue [rose 60%](https://www.sec.gov/Archives/edgar/data/0001464521/000146452126000171/htfl-20261112xex99%5F1.htm?ref=bullished.co) to $67.9 million. International and other revenue increased 29% to $4.9 million.

John Farquhar, Heartflow's president and CEO, said plaque-analysis activations were “[ramping ahead of plan](https://www.sec.gov/Archives/edgar/data/0001464521/000146452126000171/htfl-20261112xex99%5F1.htm?ref=bullished.co).” He said use was reaching a greater proportion of applicable coronary CT scans, revenue had accelerated for the third consecutive quarter, and U.S. growth was the fastest in 11 quarters.

Hospitals and outpatient imaging centers pay Heartflow for each blood-flow or plaque analysis selected by a physician. Its cloud software builds personalized 3D coronary-artery models to examine blood flow, narrowing and plaque; an integrated visualization tool helps physicians review scans. Blood-flow analysis supplied 98% of revenue in 2025.

## Better Margins, Still Higher Spending

Gross profit increased to $60.9 million from $35.4 million a year earlier. Gross margin—the share of sales left after production costs—reached 83.6%, versus 76.5%. Heartflow attributed the improvement mainly to higher case volumes, more U.S. plaque analyses and AI-related production efficiencies, partly offset by hiring and training production staff.

Adjusted gross profit was $61.1 million, versus $35.5 million, with an adjusted margin of 83.8%, up from 76.8%.

Operating expenses rose to $74.8 million from $50.5 million, which Heartflow attributed mainly to investment in sales personnel, technology and clinical research. Spending equaled 103% of revenue, versus 109% a year earlier. Adjusted expenses were $66.1 million, or 91% of revenue, against $46.7 million, or 101%.

The operating loss narrowed to $13.8 million from $15.1 million. On an adjusted basis, it fell to $5.0 million from $11.1 million.

## Last Year's Loss Had Extra Charges

Heartflow's net loss was $11.5 million, or $0.13 per share, against $50.9 million, or $1.04 per share, a year earlier. The earlier loss included a [$32.1 million](https://www.globenewswire.com/news-release/2026/11/12/3402150/0/en/heartflow-reports-third-quarter-2026-financial-results-and-raises-full-year-2026-guidance.html?ref=bullished.co) noncash charge from revaluing warrants, partly offset by a $4.8 million noncash benefit from revaluing a derivative liability.

Full repayment of its term loan in August 2025 added a $6.4 million debt-extinguishment loss. Those items make the bottom-line comparison larger than the improvement in operating losses.

Adjusted net loss narrowed to $2.7 million, or $0.03 per share, from $13.2 million, or $0.27 per share. The latest adjustment excluded $7.6 million in stock-based pay and $1.3 million in certain litigation costs.

Adjusted EBITDA—a measure excluding interest, taxes, depreciation and other adjustments—was negative $3.6 million, versus negative $9.8 million. Heartflow held $253 million in cash, cash equivalents and investments as of September 30, 2026.

The sales upgrade comes with better production margins, but quarterly operating expenses still exceeded revenue.

Learn

- [Item 2.02: results of operations →](https://www.bullished.co/learn/8-k-items-explained/#item-202-results-of-operations)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — Heartflow, Inc. (HTFL)](https://www.sec.gov/Archives/edgar/data/0001464521/000146452126000171/htfl-20261112x8k.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit htfl-20261112xex99\_1.htm — Heartflow, Inc. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001464521/000146452126000171/htfl-20261112xex99%5F1.htm?ref=bullished.co) — SEC EDGAR
- [Heartflow Reports Third Quarter 2026 Financial Results and](https://www.globenewswire.com/news-release/2026/11/12/3402150/0/en/heartflow-reports-third-quarter-2026-financial-results-and-raises-full-year-2026-guidance.html?ref=bullished.co) — globenewswire.com